Calceolarioside

Calceolarioside is a phenolic glycoside compound found in plants such as Calceolaria and Plantago species, composed of a phenylethanoid backbone linked to sugar moieties. It exerts its primary effects through free radical scavenging, inhibition of oxidative stress pathways, and potential interference with parasitic cell survival mechanisms.

Origin & History

Calceolarioside refers to phenylethanoid glycosides, primarily Calceolarioside A and B, naturally occurring in plants such as Fraxinus insularis, Plantago depressa, and night jasmine (Nyctanthes arbor-tristis). These hydroxycinnamic acid derivatives are extracted through bioactivity-guided fractionation of methanolic or polar leaf extracts.

Historical & Cultural Context

No historical or traditional medicinal uses are documented in the available sources. Current research focuses solely on modern phytochemical isolation without ethnobotanical context.

Health Benefits

• May support cardiovascular health by protecting heart cells from adriamycin-induced toxicity (preliminary in vitro evidence only)
• Exhibits antioxidant properties with IC50 values of 4.15 μM against hydroxyl radicals (preliminary in vitro evidence)
• May help combat visceral leishmaniasis infections (preliminary mouse study evidence)
• Shows potential for modulating platelet aggregation through calcium-dependent mechanisms (preliminary rabbit platelet studies)
• Demonstrates peroxynitrite scavenging activity with IC50 of 2.26 μM (preliminary in vitro evidence)

How It Works

Calceolarioside scavenges reactive oxygen species by donating hydrogen atoms from its catechol hydroxyl groups, demonstrated by an IC50 of 4.15 μM against hydroxyl radicals in vitro. It may protect cardiomyocytes by attenuating adriamycin-induced mitochondrial membrane disruption and reducing lipid peroxidation, likely through inhibition of NADPH oxidase and suppression of NF-κB-mediated apoptotic signaling. Against Leishmania donovani, it may interfere with the parasite's redox homeostasis, targeting trypanothione reductase, a thiol-metabolism enzyme absent in mammals.

Scientific Research

No human clinical trials, RCTs, or meta-analyses have been conducted on calceolarioside. Research is limited to preclinical studies including a mouse study on visceral leishmaniasis (Planta Medica, 2008) and rabbit platelet aggregation studies (Planta Medica, 1993), though specific PMIDs were not provided in the available sources.

Clinical Summary

Research on calceolarioside remains at the preclinical stage, with no published human clinical trials to date. In vitro studies have demonstrated hydroxyl radical scavenging activity with an IC50 of 4.15 μM, placing it among moderately potent natural antioxidants in cell-free assay systems. Cardioprotective effects against adriamycin-induced toxicity have been observed in isolated cell models, and antileishmanial activity has been noted in parasite culture studies, though neither finding has been validated in animal models with sufficient rigor or in human subjects. The current evidence base is insufficient to establish efficacious doses, bioavailability, or clinical relevance in any therapeutic context.

Nutritional Profile

Calceolarioside is a phenylpropanoid glycoside (phenylethanoid glycoside) compound, not a whole food ingredient, and therefore does not possess a conventional macronutrient or micronutrient profile. It has no meaningful protein, fat, carbohydrate, fiber, vitamin, or mineral content in the nutritional sense. As a pure bioactive compound, its profile is defined entirely by its chemical structure and bioactive properties: it is a glycosylated phenolic ester consisting of a caffeic acid moiety linked to a sugar backbone (typically glucose or rhamnose) and a hydroxytyrosol-related aglycone unit. Molecular weight is approximately 476–624 Da depending on the specific glycoside variant (A, B, or E forms). The compound contributes to the total polyphenol content of source plants such as species in the Calceolaria, Buddleja, and Olea genera. Its antioxidant capacity is documented at IC50 = 4.15 μM against hydroxyl radicals in vitro, indicating high molar potency relative to common antioxidants. Bioavailability is a significant constraint: as a glycoside, intestinal absorption requires hydrolysis by gut microbiota or brush-border enzymes to release the aglycone; first-pass metabolism and molecular size (~500+ Da) are expected to limit systemic bioavailability, though no specific human pharmacokinetic data (Cmax, Tmax, oral bioavailability %) are currently published. Source plant concentrations are typically in the range of 0.01–0.5% dry weight in relevant plant tissues, but no standardized dietary intake or supplemental dosage has been established.

Preparation & Dosage

No clinically studied dosages in humans are available. Preclinical studies used isolated compounds without specified standardization ranges for extracts or powders. Consult a healthcare provider before starting any new supplement.

Synergy & Pairings

Other phenylethanoid glycosides, hydroxycinnamic acids, antioxidant polyphenols, cardioprotective flavonoids

Safety & Interactions

No human safety data, clinical adverse event profiles, or tolerability studies exist for isolated calceolarioside supplementation. Because phenolic glycosides can inhibit cytochrome P450 enzymes such as CYP3A4 and CYP2C9, theoretical interactions with anticoagulants, immunosuppressants, and chemotherapeutic drugs like doxorubicin cannot be excluded. Pregnant and breastfeeding individuals should avoid calceolarioside supplements entirely due to a complete absence of reproductive safety data. Individuals with known hypersensitivity to phenylethanoid glycosides or related Plantaginaceae-family plant compounds should exercise caution.